NCT02981914View on ClinicalTrials.gov

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

October 9, 2020

Study Completion Date

November 1, 2020

Conditions
Classical Hodgkin LymphomaB-cell Non-Hodgkin LymphomaAcute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT02981914 - Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter